OncoMed nabs $93M for stem cell programs
OncoMed Pharmaceuticals, a company working to fight cancer using stem cells, added a $93 million tranche to a second round of funding that now totals $154 million. The money will be used to push its lead antibody candidate through phase-two clinical trials.
The Redwood City, Calif. firm specializes in developing treatments to target cancer stem cells — the cells that cause tumor growth and renewal. They are unique in their resistance to chemotherapy and radiotherapy treatments…. Continue Reading
Life sciences briefing: Tuesday, Dec. 11, 2007
TODAY’S HEADLINES:
Cancer stem-cell co. OncoMed strikes GSK partnership worth up to $1.4B (release)
Kosmix pulls in $10M for health, lifestyle search (release)
CDI Bioscience pulls in $3M for protein-production improvements (release)
UroMedica takes in $7M for incontinence devices (VentureWire, sub req’d)
Draths raises $2.5M for flu drugs (PE Hub)
Cancer stem-cell co. OncoMed strikes GSK partnership worth up to $1.4B – Redwood City, Calif.-based OncoMed Pharmaceuticals, a biotech founded to target and destroy the “cancer stem cells” that researchers believe may… Continue Reading